Ausgabe 4/2018
Inhalt (21 Artikel)
ASCO 2018 NSCLC highlights—combination therapy is key
Gabriele Gamerith, Florian Kocher, Jakob Rudzki, Andreas Pircher
The ASCO 2018 annual meeting: update on the adjuvant treatment of early breast cancer
Clemens Dormann, Karl J. Aichberger
ASCO 2018 highlights: metastatic breast cancer
Gabriel Rinnerthaler, Simon Peter Gampenrieder, Richard Greil
ASCO 2018: highlights in HER2-positive metastatic breast cancer
Rupert Bartsch, Elisabeth Bergen
ASCO 2018: highlights of urothelial cancer and prostate cancer
Renate Pichler, Wolfgang Horninger, Isabel Heidegger
The microbiome of the prostate
Christa Strasser, Sebastian Graf, Volkmar Tauber, Steffen Krause
Aggressive variant and treatment-related neuroendocrine prostate cancer: two different terms for the same disease?
Igor Tsaur, Christian Thomas
Lutetium-PSMA therapy—a new therapeutic option in metastatic castration-resistant prostate cancer?
Michael Ladurner, Wolfgang Horninger, Jasmin Bektic
The impact of surgery in oligometastatic prostate cancer
Jasmin Bektic, Wolfgang Horninger
Short review of biparametric prostate MRI
Fabian Steinkohl, Renate Pichler, Daniel Junker
My burning issues in neuroendocrine tumours (NET)
Barbara Kiesewetter, Markus Raderer
Cure in metastatic disease: how to manage and who is the right patient in colorectal cancer?
Thomas Gruenberger, Phillip Jonas, Rebecca Lutz, Birgit Gruenberger
Economic analysis of biomarker-based anti-EGFR therapies in metastatic colorectal cancer in the Austrian context
Dora Niedersüß-Beke, Judit Simon, Michael Schiffinger, Robert M. Mader
Significance of genetic polymorphisms in hematological malignancies: implications of risk factors for prognosis and relapse
Ali Amin Asnafi, Niloofar Farshchi, Abbas Khosravi, Neda Ketabchi, Masumeh Maleki Behzad, Saeid Shahrabi
A rare parasitic infection: visceral leishmaniasis case after gastric cancer treatment
Alkim Yolcu, Ahmet Dirican, Gamze Göksel Ozturk, Cigdem Banu Cetin, Ismet Aydogdu
Cryptococcal meningitis in an immunocompetent patient with primary myelofibrosis on long-term ruxolitinib: report of a rare case and review of literature
Amrita Chakrabarti, Nitin Sood